New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Learn More » The runaway leader in the GLP-1 market Novo Nordisk's work in the GLP-1 space has been instrumental to its success in recent years. The company's famous medicines, diabetes treatment ...

Novo Nordisk's work in the GLP-1 space has been instrumental to its success in recent years. The company's famous medicines, diabetes treatment Ozempic and anti-obesity medicine Wegovy ...

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other international dividend stocks. Dividend stocks have been grabbing investors’ attention ...

Four years ago, Dr. Darren McGuire, a cardiologist at the University of Texas Southwestern, was struggling with obesity and Type 2 diabetes. Then he started taking Ozempic, the Novo Nordisk ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

Novo Nordisk A/S's recent 44% decline combined ... The company's growth prospects remain robust, driven by diabetes and obesity treatments, with key products like Ozempic and Wegovy patent ...

Novo Nordisk said that the guidance reflects "intensifying competition and continued pricing pressure within Diabetes and Obesity care." The company is a leader in the weight-loss drug space with ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...

A breakthrough in weight loss medication is on the horizon. While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient ...

Novo Nordisk A/S is prepared for potential tariffs ... The US is a key market for Novo’s top products, including Ozempic for diabetes and the Wegovy weight-loss therapy.